Niagen Bioscience, Inc. — Director's Dealing 2016

Aug 17, 2016

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: ChromaDex Corp. (CDXC)
CIK: 0001386570
Period of Report: 2016-08-15

Reporting Person: Varvaro Thomas C (N/A)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2016-08-15	Employee Stock Options (right to buy)	$4.04	A	70000	Acquired	2026-08-15	Common Stock (70000)	Direct

Footnotes

F1: Options vest 25% on July 14, 2017 with the remainder vesting 1/36th per month over three years thereafter.